Testing a treatment plan for higher-risk testicular cancer
Part of Cancer clinical trials.
This trial checks whether a specific treatment approach works better for men with higher-risk non-seminomatous germ-cell tumors that have spread. Doctors will use tumor marker changes and where the cancer started (often the chest area) to help guide treatment choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a man age 16 or older when you sign consent
- Have non-seminomatous germ-cell tumor (NSGCT) confirmed by biopsy or strongly suggested by blood tests (hCG/AFP)
- Have cancer that has spread (stage II or III) and is considered “poor risk” by set blood/clinical criteria
- Cancer must have started in the testicle, lower belly (retroperitoneum), or chest (mediastinum)
- Have enough kidney, bone marrow, and liver health on lab tests (kidney clearance over 60 mL/min; blood counts adequate; bilirubin not too high)
- Agree to birth-control during the study and for 6 months after the last treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study compares two ways of checking your cancer follow-up: a doctor or nurse visits in person versus remote monitoring by phone and imaging. The goal is to see whether remote monitoring can safely replace or match in-person care for certain low-risk cancers and after surgery.
This trial tests if adding a drug called paclitaxel to the standard chemotherapy combination (BEP) can improve outcomes for people with aggressive testicular cancer. It is for those whose tumor markers did not drop as fast as expected after the first round of chemo.
This study looks at how to manage germ cell tumors in children and young adults using careful monitoring for some patients and chemotherapy for others. It aims to see whether these approaches can control the cancer while avoiding unnecessary treatment when possible.
This trial tests whether a less intensive treatment can be used for testicular seminoma that has spread to nearby lymph nodes but is still small (under 3 cm). It aims to keep the cure rate high while reducing side effects.
This Phase 3 trial compares a faster chemotherapy approach versus the standard schedule for people with intermediate- or poor-risk metastatic germ cell tumors. The goal is to see which schedule works better and is safer enough to use as initial treatment.
This trial tests a second-line high-dose chemotherapy for germ cell tumors that have come back after initial treatment. It may be an option for patients whose cancer progressed after 3–4 cycles of standard platinum-based chemo.
Hear when a new Non-Seminomatous Germ Cell Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.